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Abstract
Studies have shown that estrogen replacement therapy and estrogen plus progestin replacement therapy alter serum levels of 
total, LDL and HDL cholesterol levels. However, HDL cholesterol levels in women vary considerably in response to hormone 
replacement therapy (HRT). A significant portion of the variability of these levels has been attributed to genetic factors. There-
fore, we investigated the influence of estrogen receptor-alpha (ESR1) gene polymorphisms on HDL levels in response to post-
menopausal HRT. We performed a prospective cohort study on 54 postmenopausal women who had not used HRT before the 
study and had no significant general medical illness. HRT consisted of conjugated equine estrogen and medroxyprogesterone 
acetate continuously for 1 year. The lipoprotein levels were measured from blood samples taken before the start of therapy 
and after 1 year of HRT. ESR1 polymorphism (MspI C>T, HaeIII C>T, PvuII C>T, and XbaI A>G) frequencies were assayed by 
restriction fragment length polymorphism. A general linear model was used to describe the relationships between HDL levels 
and genotypes after adjusting for age. A significant increase in HDL levels was observed after HRT (P = 0.029). Women with 
the ESR1 PvuII TT genotype showed a statistically significant increase in HDL levels after HRT (P = 0.032). No association 
was found between other ESR1 polymorphisms and HDL levels. According to our results, the ESR1 PvuII TT genotype was 
associated with increased levels of HDL after 1 year of HRT.
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Estrogen exerts beneficial systemic effects on lipoprotein 
and antioxidant metabolism through estrogen receptor-
alpha (ESR1) (1). It is clear that estrogen levels decline in 
women during menopause and that this is one reason for the 
increase in plasma low-density lipoprotein (LDL) levels. LDL 
is one of the lipoproteins that promote endothelial damage, 
as well as reduction of high-density lipoprotein (HDL), a 
pleiotropic lipoprotein that prevents or alleviates endothelial 
damage (2). Studies have shown that estrogen replacement 
therapy and estrogen plus progestin replacement therapy 
alter these levels by decreasing LDL cholesterol levels and 
increasing HDL cholesterol levels (3,4). However, HDL 
cholesterol levels in women vary considerably in response 
to hormone replacement therapy (HRT) and a significant 
portion of the variability in HDL cholesterol levels can be 
attributed to genetic factors (5-7). 
ESR1 is a member of a nuclear hormone receptor 
superfamily and acts as a ligand-activated transcription 
factor composed of several domains that are important for 
hormone and DNA binding (8). The human ESR1 gene is 
located on the long arm of chromosome 6 (6q25.1) and 
contains 8 exons separated by 7 intronic regions (9,10). 
Several single nucleotide polymorphisms (SNP) of the ESR1 
gene have been identified, of which the MspI C>T (National 
Center for Biotechnology Information SNP identification, 
NCBI SNP ID: rs1784705) SNP in the first exon and HaeIII 
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C>T (NCBI SNP ID: rs9322331), PvuII C>T (NCBI SNP ID: 
rs2234693) and XbaI A>G (NCBI SNP ID: rs9340799). SNP 
in the first intron have been studied the most. For example, 
polymorphic alterations of the ESR1 gene have been evalu-
ated in studies of possible linkage and/or association with 
endometrial cancer (11), breast cancer (12), ovarian cancer 
(13), prostate cancer (14), leiomyoma (15,16), endometrio-
sis (16-18), bone mineral density (19,20), and cardiovascular 
disease (21) with discrepant results in studies that included 
a very different number of patients. However, very few of 
them were designed to compare the same patient before 
and after HRT.
Data concerning an association of ESR1 genetic poly-
morphisms with lipid profiles in postmenopausal women 
have been contradictory. Some studies of postmenopausal 
women did not detect an association between ESR1 
polymorphisms and serum lipoprotein levels after HRT 
(22-25). However, Herrington et al. (26) reported that post-
menopausal women who were ESR1 PvuII CC carriers, 
as well as those with several other closely linked intron 1 
polymorphisms, had an increase in HDL cholesterol levels 
after HRT. Later, these results were supported by the obser-
vation that postmenopausal women with an ESR1 PvuII CC 
genotype had an increase response of HDL, apolipoprotein 
A1, vascular reactivity, and myocardial perfusion to HRT 
(27). On the other hand, Huang et al. (28) have reported 
that healthy postmenopausal women with the CC or TC 
genotype in ESR1 PvuII restriction had higher serum total 
cholesterol and LDL cholesterol concentrations. 
The objective of the present study was to determine if 
there is an association between MspI C>T, HaeIII C>T, PvuII 
C>T, and XbaI A>G ESR1 SNP and plasma HDL cholesterol 
levels in postmenopausal women who were treated with 
conjugated equine estrogen and medroxyprogesterone 
acetate continuously for 1 year.
Material and Methods
One hundred non-hysterectomized and postmeno-
pausal women were enrolled in the study, which was ap-
proved by the Ethics Committee of the Federal University 
of São Paulo (Brazil). All patients gave written informed 
consent to participate. No patient had been previously 
treated with HRT and all had a maximum of 3 years of 
menopause. Other exclusion criteria were a history of breast 
or endometrial cancer, deep vein thrombosis, uncontrolled 
hypertension, valvular or congenital heart disease, heart 
failure, cardiomyopathy, diabetes, and renal or thyroid 
disease. Fifty-four women were initially included, after 46 
had been excluded due to thyroid, kidney, liver, and/or 
diabetes problems.
HRT consisted of 0.625 mg/day conjugated equine 
estrogen and 2.5 mg/day medroxyprogesterone acetate 
continuously for 1 year, with a medical visit every 3 months. 
Blood samples were obtained between 8 and 9 am after 
overnight fasting before and after 1 year of treatment for 
the determination of HDL levels on day zero (HDLpre) 
and after 1 year of treatment (HDLpost). All samples were 
analyzed immediately after collection. Routine chemical 
methods were used to determine lipoprotein levels (Bayer 
Healthcare, USA).
Genomic DNA was extracted from peripheral blood 
leukocytes using the Easy-DNA™ Kit (Invitrogen Corpora-
tion, USA) according to manufacturer instructions. The DNA 
(0.2 μg) was amplified in 50 μL PCR Master Mix (Promega 
Corporation, USA). Five micromoles per microliter of oli-
gonucleotide primer set was used for each reaction. The 
polymerase chain reaction (PCR) was performed for 35 
cycles to amplify each specific fragment of the ESR1 gene. 
The PCR conditions, oligonucleotide primers, and genotype 
sizing were described elsewhere (26,29,30).
After PCR amplification, the polymorphisms were 
assayed using restriction fragment length polymorphism 
(RFLP). Each PCR product was incubated with 3 units of 
a specific restriction enzyme at 37°C for 4 h and the result-
ing fragments were visualized on a 3% ethidium bromide-
stained agarose gel using UV light and documented with a 
digital camera (Eastman Kodak Co., USA). Genotypes for 
MspI, HaeIII, and PvuII polymorphisms were termed CC/
CT/TT, and XbaI polymorphisms were AA/AG/GG and CC/
CT/TT, respectively. 
The chi-square test was used to test for significant 
departures from Hardy-Weinberg equilibrium. Pairwise 
linkage disequilibrium (D’) was calculated using the linkage 
disequilibrium pairs program from the GENECOUNTING 
utilities (31) and the WHAP software (http://pngu.mgh. 
harvard.edu/~purcell/whap/) was used to estimate haplo-
type frequencies. HDL levels were calculated during the trial 
as mean follow-up measurements obtained before (HDLpre) 
and after (HDLpost) treatment. A general linear model was 
used to describe the relationships between HDL levels and 
various genotypes after adjusting for age. A paired sample 
t-test and one-way ANOVA were employed for within- and 
between-group comparisons, respectively.
Results
Fifty-four women started the treatment. Mean age (± 
SD) was 51.7 ± 3.6 years. Plasma HDL levels were 55.33 
± 14.49 mg/dL before and 58.24 ± 14.36 mg/dL after HRT. 
A significant difference in HDL levels was observed before 
and after HRT (P = 0.029). After HRT, HDL levels were 
maintained or decreased in 35.2% (N = 19) of these post-
menopausal patients, but were increased in the remaining 
64.8% (N = 35).
The genotype frequencies of the estrogen receptor-
alpha gene polymorphisms ESR1 MspI C>T, ESR1 HaeIII 
C>T, ESR1 PvuII C>T, and ESR1 XbaI A>G are shown 
in Table 1. The four ESR1 SNP were in Hardy-Weinberg 
equilibrium (P > 0.05). The three ESR1 SNP in intron 1 
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were in linkage disequilibrium with each other (HaeIII 
C>T with PvuII T>C; HaeIII C>T with XbaI A>G and XbaI 
A>G with PvuII C>T; D’ = 1.000; P < 0.0001). No linkage 
disequilibrium was observed between the SNP in exon 1 
and the SNP in intron 1.
We analyzed the genotype of the ESR1 gene together 
with plasma HDL levels before and after HRT (Table 1). 
After 1 year of HRT, we observed an increase in plasma 
HDL levels in all ESR1 genotypes. There was no significant 
difference in HDLpre or HDLpost levels in ESR1 MspI geno-
types (MspI CC: P = 0.786; MspI CT: P = 0.069; MspI TT: 
P = 0.191), ESR1 HaeIII genotypes (HaeIII CC: P = 0.074; 
HaeIII CT: P = 0.518; HaeIII TT: P = 0.241), or ESR1 XbaI 
genotypes (XbaI AA: P = 0.142; XbaI AG: P = 0.417; XbaI 
GG: P = 0.101). However, in ESR1 PvuII genotypes, PvuII 
TT carriers showed a statistically significant increase in HDL 
levels after HRT (P = 0.032). In the other PvuII genotypes, 
the increase of HDL levels was not significantly different 
after HRT (PvuII CC: P = 0.246; PvuII CT: P = 0.592).
Analyses using the mean difference in HDL levels as a 
quantitative trait did not provide evidence of an association 
for the following haplotypes: i) alleles of the four markers 
(likelihood ratio test, LRT = 0.370; P = 0.831); ii), the strongly 
linked combination of ESR1 HaeII, ESR1 PvuII and ESR1 
XbaI (LRT = 3.11; P = 0.370); iii) the ESR MspI/ESR1 HaeII 
combination (LRT = 0.563; P = 0.755); iv), the ESR1 HaeII/
ESR1 PvuII combination (LRT = 1.22; P = 0.544), and v) 
the ESR1 PvuII and ESR1 XbaI combination (LRT = 3.10; 
P = 0.210).
Discussion
Endogenous and exogenous estrogens have been re-
ported to affect the hemostatic system and to exert effects 
on lipoprotein metabolism (2,3). In the present study, we de-
termined whether estrogen receptor-alpha (ESR1 MspI C>T, 
HaeIII C>T, PvuII C>T, and XbaI A>G) gene polymorphisms 
are associated with high HDL levels in women undergoing 
postmenopausal hormone replacement therapy. ESR1 PvuII 
TT carriers showed a statistically significant increase in HDL 
levels after HRT (HDLpre = 53.25 ± 15.70; HDLpost = 57.60 
± 14.35; P = 0.032). No association was found between the 
three other polymorphisms and HDL levels.
The previous in vitro observations of allele-dependent 
differences of ESR1 PvuII polymorphisms and HDL levels 
are contradictory. Herrington et al. (6) showed that the 
ESR1 PvuII T allele eliminates a functional binding site for 
the transcription factor Myb, which suggests that the pres-
ence of this allele may result in lower ESR1 transcription, 
and postmenopausal PvuII CC carriers showed increased 
HDL cholesterol levels in response to HRT (26). However, 
Figtree et al. (32) showed that the variant T allele of ESR1 
PvuII abolished the negative transcriptional regulation by 
an adjacent glucocorticoid receptor binding sequence, and 
was strongly associated with HDL levels in a large cohort 
of postmenopausal women. Moreover, they suggested that 
the functional promoter variant associated with increased 
HDL might act by increasing ESR1 expression and that the 
ESR1 PvuII polymorphism may also alter both beneficial and 
detrimental responses to exogenous estrogen administered 
in the form of HRT.
Importantly, we observed a significant increase of HDL 
levels in this postmenopausal group after HRT. In this 
regard, it would be interesting to suggest that for patients 
with low HDL levels the genotyping procedure could define 
more accurately the type of patient who would benefit from 
HRT. Moreover, only PvuII TT carriers, but not PvuII CC 
carriers, had a significant increase in HDL levels after 1 year 
of hormone replacement. The limitation of our study is the 
relatively small number of patients included. However, a 
strength of our study is that it is a prospective study of the 
Brazilian population, comparing the same women before 
and after HRT to address the question of whether or not 
HDL levels are associated with the ESR1 genotype.
We showed here that in our sample of Brazilian post-
menopausal women with the ESR1 PvuII TT genotype, 
there is a significantly higher serum HDL lipoprotein con-
centration after HRT than in women with the PvuII CC or 
CT genotype.
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Table 1. Genotype frequencies and high-density lipoprotein lev-
els before (HDLpre) and after (HDLpost) hormone replacement 
therapy in each estrogen receptor-alpha polymorphism.
Genotype Frequency (%) HDLpre HDLpost 
MspI CC 7 (13) 57.29 ±  9.99 58.57 ± 13.08
MspI CT 25 (46) 52.44 ± 14.24 55.96 ± 15.78
MspI TT 22 (41) 58.00 ± 15.84 60.73 ± 13.19
HaeIII CC 38 (70) 55.58 ± 15.06 58.16 ± 13.46
HaeIII CT 12 (22) 53.92 ± 12.66 56.25 ± 15.33
HaeIII TT 4 (8) 57.25 ± 17.67 65.00 ± 21.67
PvuII CC 11 (20) 57.64 ± 18.08 61.64 ± 17.40
PvuII CT 23 (43) 56.04 ± 11.72 57.17 ± 13.19
PvuII TT 20 (37) 53.25 ± 15.70 57.60 ± 14.35*
XbaI AA 28 (52) 56.36 ± 14.49 58.93 ± 14.34
XbaI AG 21 (39) 54.14 ± 12.05 55.95 ± 13.51
XbaI GG 5 (9) 54.60 ± 16.41 64.00 ± 18.90
Data are reported as means ± SD in mg/dL. *P < 0.05, HDLpost 
compared to HDLpre (t-test).
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